Embedded Files
DelveInsight's "Heart Failure Pipeline Analysis 2025" delivers extensive intelligence on over 70 pharmaceutical firms and more than 75 investigational medications within the Heart Failure development arena. The analysis encompasses profiles of Heart Failure pipeline therapeutic candidates, spanning both clinical and preclinical phases. Additionally, it includes evaluation of Heart Failure pipeline therapeutics by product category, developmental phase, administration method, and molecular classification. The report also spotlights dormant development programs in this therapeutic area.
Examine the comprehensive intelligence by DelveInsight and remain informed about the Heart Failure Treatment Landscape @ Heart Failure Pipeline Outlook
Primary Highlights from the Heart Failure Pipeline Analysis
Primary Highlights from the Heart Failure Pipeline Analysis
November 6, 2025, Bristol-Myers Squibb initiated an investigation to evaluate the safety profile, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF). DelveInsight's Heart Failure pipeline analysis reveals a dynamic field featuring more than 70 engaged entities advancing over 75 investigational treatments for Heart Failure management.
The Heart Failure pharmaceutical firms include Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics, among additional organizations.
Notable Heart Failure Pipeline investigational medications include Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, Dapagliflozin, among others.
Remain informed about the cutting-edge advancements in Heart Failure treatments. Access updates and participate in the revolution in Cardiovascular Diseases Care @ Heart Failure Clinical Trials Assessment
The Heart Failure Pipeline Analysis delivers a condition synopsis, pipeline landscape, and therapeutic evaluation of principal investigational therapies within this domain. The analysis also emphasizes unaddressed medical requirements concerning Heart Failure.
Heart Failure Background
Heart Failure Background
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF include increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations.
Heart Failure Investigational Drug Profiles
Heart Failure Investigational Drug Profiles
Rexlemestrocel-L: Mesoblast
Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Enrollment of 566 patients has been completed in a placebo-controlled Phase III trial to evaluate a single dose of Revascor in Class II/III CHF patients across multiple sites in North America. Patients with advanced heart failure constitute the majority of the patients enrolled in this clinical trial program. Presently, the medication is undergoing Phase III developmental assessment for heart failure management.
HU 6: Rivus Pharmaceuticals
HU6 is a controlled metabolic accelerator (CMA) that provides a novel, measured approach to activating proton leak and mitochondrial uncoupling, a natural process in the body that regulates and dissipates energy. By ferrying protons out of the mitochondrial intermembrane space, CMAs cue the increased oxidation of sugars and fats, while maintaining the same baseline production of adenosine triphosphate (ATP). Activating this process results in the reduction of accumulated fat throughout the body. Presently, the medication is undergoing Phase II developmental assessment for heart failure management.
HS-001: Heartseed Inc
HS-001, is allogeneic iPSC-derived, highly purified ventricular cardiomyocyte spheroids. By forming micro-tissue-like spheroids, retention rate and viability of cell transplant are improved. The spheroids are transplanted using a special administration needle (SEEDPLANTER®) and guide adapter developed for the administration of the spheroids into the myocardial layer of the heart. The expected mechanism of action is that the transplanted cardiomyocytes electrically couple with the patient's myocardium to improve cardiac output by remuscularisation, and secretion of angiogenic factors to form new blood vessels around the transplant site (neovascularization). In June 2021, Heartseed and Novo Nordisk entered into global collaboration and license agreement for stem cell-based therapy for heart failure. Presently, the medication is undergoing Phase I/II developmental assessment for heart failure management.
Ribonucleotide reductase based gene therapy: StemCardia
Ribonucleotide reductase based gene therapy is a novel investigational product candidate under development by StemCardia. The therapeutic candidate is based on Gene transference and Ribonucleotide reductase modulators mechanism of action. Presently, the medication is in preclinical developmental stage for heart failure management.
Discover more about Heart Failure therapeutic opportunities in our groundbreaking Heart Failure research and development initiatives @ Heart Failure Unmet Needs
The Heart Failure Pipeline Analysis Offers Intelligence On
The Heart Failure Pipeline Analysis Offers Intelligence On
The analysis delivers detailed intelligence regarding pharmaceutical companies developing therapeutics for Heart Failure management, including cumulative therapies created by each organization for this indication. It evaluates various therapeutic candidates categorized into early-phase, mid-phase, and late-phase development for Heart Failure Treatment. Heart Failure pharmaceutical firms engaged in targeted therapeutic development with corresponding active and inactive (dormant or terminated) initiatives. Heart Failure investigational medications classified by developmental phase, administration method, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular classification. Comprehensive analysis of partnerships (company-to-company collaborations and company-to-academia partnerships), licensing arrangements, and funding particulars for future progression of the Heart Failure market.
Heart Failure Pharmaceutical Firms
Heart Failure Pharmaceutical Firms
Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics, among additional organizations.
The Heart Failure pipeline analysis presents therapeutic evaluation of investigational medications by Administration Method. Products are classified under multiple administration routes including:
Oral Intravenous Subcutaneous Parenteral Topical
Heart Failure products are classified under various molecular categories including:
Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy
Remain informed about how we're transforming the future of Cardiovascular Diseases @ Heart Failure Market Drivers and Barriers, and Future Perspectives
Scope of the Heart Failure Pipeline Analysis
Scope of the Heart Failure Pipeline Analysis
Coverage- Global
Heart Failure Companies- Mesoblast, Rivus Pharmaceuticals, Heartseed Inc, StemCardia, Eli Lilly and Company, BioCardia, Bristol Myers Squibb, Sardocor Corp., AstraZeneca, Tenaya Therapeutics, Salubris Bio Therapeutics, Moderna Therapeutics, Cytokinetics, Applied Therapeutics, Help Therapeutics, Stealth BioTherapeutics, Actelion Pharmaceuticals, Bayer HealthCare Pharmaceuticals/Merck & Co, Servier, Lexicon Pharmaceuticals, Windtree Therapeutics and others.
Heart Failure Pipeline Therapies- Pirfenidone, KW-3902IV, Relaxin, Tolvaptan, Furosemide, Torsemide, Bumetanide, GSK716155, Dapagliflozin and others.
Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a comprehensive overview of our latest research findings and future plans, access the complete details of Heart Failure Pipeline on our website @ Heart Failure Emerging Drugs and Companies
Table of Contents
Table of Contents
Introduction
Executive Summary
Heart Failure: Overview
Pipeline Therapeutics
Therapeutic Assessment
Heart Failure – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Rexlemestrocel-L: Mesoblast
Mid Stage Products (Phase II)
HU 6: Rivus Pharmaceuticals
Early Stage Products (Phase I/II)
HS-001: Heartseed Inc
Preclinical and Discovery Stage Products
Ribonucleotide reductase-based gene therapy: StemCardia
Inactive Products
Heart Failure Key Companies
Heart Failure Key Products
Heart Failure - Unmet Needs
Heart Failure - Market Drivers and Barriers
Heart Failure - Future Perspectives and Conclusion
Heart Failure Analyst Views
Heart Failure Key Companies
Appendix
About Us
About Us
DelveInsight is a premier healthcare-oriented market research and advisory organization that delivers clients superior market intelligence and analysis to facilitate informed business strategies. Supported by a team of seasoned industry specialists and comprehensive knowledge of the life sciences and healthcare industries, we provide tailored research solutions and strategic insights to clients worldwide. Partner with us to obtain superior-quality, precise, and current intelligence to maintain competitive advantage.
Contact Us
Contact Us
Kanishk
Page updated
Report abuse